Abstract
Lignocaine clearance declines during continuous intravenous infustion in man and in vitrostudies suggest that this may partly be due to inhibition by MEGX, a metabolite of lignocaine, MEGX is pharmacologically active in animals, but this is not yet proven in man. This study examined the pharmacokinetics and pharmacodynamics of lignocaine and MEGX in eight healthy male volunteers given lignocaine HCl 120mg, MEGX HCl 120 mg, lignocaine HCl 120 mg+MEGX HCl 120 mg, and placebo, administered according to a randomized double-blind protocol. One-, two-, or three-compartment models were fitted to drug and metabolite blood concentration-time profiles and clearance, volume (V ss ), andhalf-life values were calculated and compared by paired t-test. Systolic time intervals and QTinterval were recorded and compared by repeated measures ANOVA. When administered in combination with MEGX, lignocaine clearance was significantly reduced from 58±18 to 48±13 L hr(su−1) (p <0.02). The V(inss) was unchanged and there was a trend toward an increase in terminal half-life. Lignocaine, MEGX, and the combination significantly reduced QTinterval up to 30 min after injection and this was maintained to 2 hr with the lignocaine and the combination. Transient side effects were experienced with all active treatments, but were most pronounced with the combination. Thus, lignocaine clearance was inhibited by MEGX, which was pharmacologically active in man.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
J. LeLorier, D. Grenon, Y. Latour, G. Caille, G. Dumont, A. Brosseau, and A. Solignac. Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction.Ann. Intern. Med. 87:700–702 (1977).
L. F. Prescott, K. K. Adjepon-Yamoah, and R. G. Talbot. Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure.Br. Med. J. 1:939–941 (1976).
L. A. Bauer, T. Brown, M. Gibaldi, L. Hudson, S. Nelson, V. Raisys, and J. P. Shea. Influence of longterm infusions on lidocaine pharmacokinetics.Clin. Pharmacol. Ther. 31:433–437 (1982).
S. E. Joel, S. M. Bryson, M. Small, W. S. Hillis, A. W. Kelman, and B. Whiting. Kinetic predictive techniques applied to lignocaine therapeutic drug monitoring.Ther. Drug Monit. 5:271–277 (1983).
A. Barchowsky, W. W. Stargel, D. G. Shand, and P. A. Routledge. On the role of alpha-1-acid glycoprotein in lignocaine accummulation following myocardial infarction.Br. J. Clin. Pharmacol. 13:411–415 (1982).
J. LeLorier, R. Moison, J. Gagne, and G. Caille. Effect of the duration of infusion on the disposition of lidocaine in dogs.J. Pharmacol. Exp. Ther. 203:507–511 (1977).
M. S. Lennard, G. T. Tucker, and H. F. Woods. Time-dependent kinetics of lignocaine in the isolated perfused rat liver.J. Pharmacokin. Biopharm. 11:165–182 (1983).
T. Suzuki, S. Fujita, and R. Kawai. Precursor-metabolite interaction in the metabolism of lignocaine.J. Pharm. Sci. 73:136–138 (1984).
J. M. Strong, D. E. Mayfield, A. J. Atkinson, B. C. Burris, F. Raymon, and L. T. Webster. Pharmacological activity, metabolism and pharmacokinetics of glycinexylidide.Clin. Pharmacol. Ther. 17:184–194 (1975).
R. G. Burney, G. A. DiFazio, M. J. Peach, K. A. Petrie, and M. J. Sylvester. Antiarrhythmic effects of lidocaine metabolites.Am. Heart J. 88:765–769 (1974).
H. Halkin, P. Meffin, K. L. Melmon, and M. Rowland. Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite.Clin. Pharmacol. Ther. 17:669–676 (1975).
R. L. Nation, E. J. Triggs, and M. Selig. Lignocaine kinetics in cardiac patients and aged subjects.Br. J. Clin. Pharmacol. 4:439–448 (1977).
A. H. Beckett, R. N. Boyes, and P. J. Appleton. The metabolism and excretion of lwignocaine in man.J. Pharm. Pharmacol. 18(Suppl.):76s-81s. (1966).
R. L. Nation, G. W. Peng, and W. L. Chiou. High pressure liquid chromatographic method for simultaneous determination of lidocaine and its N-dealkylated metabolite in plasma.J. Chromatogr. 162:466–473 (1979).
L. B. Sheiner. ELSFIT (Users Manual). Division of Clinical Pharmacology, University of California, San Francisco, 1983.
M. Gibaldi and D. Perrier.Pharmacokinetics, Marcel Dekker, New York, 1975.
A. W. Kelman and D. J. Sumner. Systolic time interval v heart rate regression equations using atropine: Reproducibility studies.Br. J. Clin. Pharmacol. 12:15–20 (1981).
B. J. Winer.Statistical Problems in Experimental Design, 2nd ed., McGraw-Hill, New York, 1971.
M. Rowland, P. D. Thomson, A. Giuchard, and K. L. Melmon. Disposition kinetics of lidocaine in normal subjects.Ann. N. Y. Acad. Sci. 179:383–398 (1971).
N. O. Benowitz and W. Meister. Clinical pharmacokinetics of lidocaine.Clin. Pharmacokin. 3:177–201 (1978).
A. H. Thomson, A. W. Kelman, P. J. de Vane, W. S. Hillis, and B. Whiting. Bayesian parameter estimation: Comparison of one and two compartment models for lignocaine. InProceedings of the Second European Congress on Biopharmaceutics and Pharmacokinetics, Salamanca, Spain, 1984.
K. K. Adjepon-Yamoah and L. F. Prescott. Lignocaine metabolism in man.Br. J. Pharmacol. 47:672p-673p (1973).
P. N. Bennett, L. J. Aarons, M. R. Bending, J. A. Steiner, and M. Rowland. Pharmacokinetics of lidocaine and its dethylated metabolite: Dose and time dependency studies in man.J. Pharmacokin. Biopharm. 10:265–281, (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomson, A.H., Elliott, H.L., Kelman, A.W. et al. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. Journal of Pharmacokinetics and Biopharmaceutics 15, 101–115 (1987). https://doi.org/10.1007/BF01062338
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062338